Nutritional Growth Solutions Ltd. announced the commencement of clinical trial to evaluate the effect of its innovative sports supplement on the physical activity performance of young soccer players. The clinical trial will be a randomised, double-blind, placebo-controlled pilot that will recruit up to 50 healthy soccer players ages 8 to 15 years old, to determine the efficacy and safety of the new supplement versus placebo. The clinical trial comprises of an 8-week treatment period followed by an 8-week open-label period, with initial results expected in Third Quarter 2023.

The NGS innovative nutritional supplement supplies a boost of nutritious energy, and contains high quality whey proteins, additional specific amino acids, creatine monohydrate, carbohydrates, fats, and micronutrients (including calcium, iron, zinc, magnesium, vitamin A, vitamin C, vitamin D, vitamin E and vitamin B complex). Research has shown that lacking sufficient calories, macro and micro-nutrients may impair an athlete's training adaptations, while athletes who consume a balanced diet that meets energy needs can enhance physiological training adaptations. Maintaining an energy and nutrient deficient diet during training may lead to loss of muscle mass, strength, and bone mineral density, in addition to an increased susceptibility to illness and injuries, disturbances in immune, endocrine and reproductive function, and an increased prevalence of overreaching and/or overtraining.

Incorporating good dietary practices as part of a training program is one way to help optimise training adaptations and prevent overtraining. In the current trial, the Company will run multiple tests, including: 10m and 20m sprints, countermovement jumps, agility tests, endurance tests, anthropometric assessments (height, weight and BMI) and body composition.